Amgen to pay $762M in improper drug marketing
Drug maker Amgen will pay $762 million to settle litigation that accuses the drugmaker of marketing the anemia drug Aranesp for unapproved uses. A law firm involved in the case says the Thousand Oaks, Calif., company will pay a $612 million civil settlement, $136 million in criminal fines and a $14 million forfeiture. Credit: Handout
Amgen will pay $762 million to settle litigation that accuses the drugmaker of marketing the anemia drug Aranesp for unapproved uses.
A law firm involved in the case says the Thousand Oaks, Calif., company will pay a $612 million civil settlement, $136 million in criminal fines and a $14 million forfeiture.
Amgen Inc. says it entered a conditional guilty plea to a misdemeanor count of misbranding Aranesp. The company took a $780 million charge last year for a possible settlement.
Amgen develops biologic medicines, or drugs produced by living cells rather than by mixing chemicals. Its settlement marks the latest between the U.S. Department of Justice and a drugmaker over improper marketing allegations.
Doctors can prescribe drugs for unapproved uses, but companies aren't allowed to market drugs for those uses.
Out East: Mecox Bay Dairy, Kent Animal Shelter, Custer Institute & Observatory and local champagnes NewsdayTV's Doug Geed takes us "Out East," and shows us different spots you can visit this winter.
Out East: Mecox Bay Dairy, Kent Animal Shelter, Custer Institute & Observatory and local champagnes NewsdayTV's Doug Geed takes us "Out East," and shows us different spots you can visit this winter.
